PROVECTUS PHARMACEUTICALS

About PROVECTUS PHARMACEUTICALS

Provectus Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing and commercializing a new class of drugs based on its proprietary small molecule, Rose Bengal disodium. The company, headquartered in Knoxville, Tennessee, was founded in 2002. The current leadership includes President, CEO, & Chairman of the Board, Ed Persky.

The company's lead investigational drug is PV-10, an injectable formulation of Rose Bengal disodium designed for the intralesional treatment of solid tumors. PV-10 is classified as an ablative immunotherapy, meaning it is designed to selectively destroy cancerous tumors through chemoablation while also stimulating the immune system to attack both local and distant tumors. This dual mechanism of action is a key differentiator. The primary application under investigation is for melanoma, but research extends to other solid tumors like cancers of the liver. Provectus is also developing PH-10, a topical formulation of Rose Bengal, for the treatment of inflammatory dermatoses such as psoriasis and atopic dermatitis.

Provectus operates in the biopharmaceutical market, concentrating on oncology and dermatology. Its business model centers on advancing its drug candidates through the clinical trial phases to gain regulatory approval from bodies like the FDA. The company collaborates with leading cancer research centers and has an intellectual property portfolio that includes multiple patents for its technology and methods. Revenue generation is anticipated upon the successful commercialization of its drug candidates through direct sales or licensing agreements with larger pharmaceutical partners.